Haphazard Proliferation of Cytologically and Mesothelioma Tumors
An interesting study is called, "Intrapulmonary localized fibrous tumor
. Intraparenchymal so-called localized fibrous mesothelioma." By Yousem SA, Flynn SD - Am J Clin Pathol. 1988 Mar;89(3):365-9. Here is an excerpt: "Abstract - This report describes three cases of intrapulmonary fibromas which are histologically identical to localized fibrous tumors of pleura (localized fibrous mesothelioma). Morphologically these tumors are characterized by a haphazard proliferation of cytologically bland spindle cells separated by variable amounts of wavy hyalinized collagen. Entrapped bronchiolar and alveolar epithelium is common. These spindle cells lack expression of cytoplasmic keratin, S-100 protein, desmin, and epithelial membrane antigen, but are strongly decorated for intracellular vimentin. The clinical behavior, differential diagnosis, and histogenesis of these lesions are discussed."
Another interesting study is called, "Posttranscriptional regulation of urokinase receptor mRNA: identification of a novel urokinase receptor mRNA binding protein in human mesothelioma cells" by S Shetty, A Kumar and S Idell - Department of Medicine, University of Texas Health Science Center, Tyler 75710, USA. Mol. Cell. Biol., 03 1997, 1075-1083, Vol 17, No. 3 American Society for Microbiology. Here is an excerpt: "Treatment of human pleural mesothelioma (MS-1) cells with phorbol myristate acetate (PMA) and cycloheximide results in 17- and 10-fold, respectively, increases in steady-state expression of urokinase-type plasminogen activator receptor (uPAR) mRNA. Studies of transcriptional inhibition by actinomycin D showed four- and sixfold extensions of uPAR mRNA half-life in MS-1 cells treated with PMA and cycloheximide, respectively, suggesting that uPAR gene expression involves a posttranscriptional regulatory mechanism. Using gel mobility shift and UV cross-linking assays, we identified a 50-kDa uPAR mRNA binding protein (uPAR mRNABp) that selectively bound to a 51-nucleotide (nt) fragment of mRNA corresponding to the uPAR coding region. We investigated the possibility that this 51-nt protein binding fragment of uPAR mRNA contains regulatory information for message stability. Chimeric beta-globin/uPAR/beta-globin mRNA containing the 51-nt protein binding fragment was able to destabilize otherwise stable beta-globin mRNA. Conversely, a control chimeric beta-globin/uPAR/beta-globin mRNA containing a 51-nt fragment of the uPAR coding region that does not bind uPAR mRNABp was stable under identical conditions. Binding of uPAR mRNABp to uPAR mRNA was abolished after treatment with cycloheximide and rapidly down-regulated by PMA. These data suggest that the 51-nt protein binding fragment of uPAR mRNA may be involved in mRNA turnover as well as in cycloheximide-induced uPAR message stabilization. Our results indicate a novel mechanism of uPAR gene regulation in which cis elements within a 51-nt coding region interact with a uPAR mRNABp to regulate uPAR message stability."
One interesting study is called, "Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant Mesothelioma" -
Oxford Journals Medicine Annals of OncologyVolume9, Issue 3 Pp. 269-273 by
G. W. Middleton, I. E. Smith, M. E. R. O'Brien, A. Norton, T. Hickish, K. Priest, L. Spencer and S. Ashley Here is an excerpt: "Abstract - Purpose: To evaluate the therapeutic impact of a simple combination chemotherapy regimen on symptoms related to malignant mesothelioma. Materials and methods: Between October 1986 and June 1997, 39 patients with advanced inoperable malignant mesothelioma were treated with palliative MVP (mitomycin-C 8 mg/ m q. six weeks, vinblastine 6 mg/2 q. three weeks and cisplatin 50 mg/m2 q. three weeks) chemotherapy and assessed for objective response and relief of symptoms. Results: Eight of 39 patients (20%) achieved an objective partial response with a median duration of nine months: only five patients had progression of disease during chemotherapy. Twenty-four of 39 (62%) had an overall improvement in their symptomology with particularly good responses for pain (79%). These benefits were independent of performance status. Resolution of symptoms was achieved in all responding patients within two treatment cycles. There was no statistically significant difference in duration and incidence of symptom response in those patients achieving radiological PR compared with those with no change and more than 60% of patients with radiological no change obtained useful symptom control. The treatment was well tolerated with only four patients developing grade 3 leucopenia and three with grade 3 nausea. Conclusions: MVP is a well tolerated regimen and its use in malignant mesothelioma provides useful symptomatic benefit. These results should be the basis for further trials of MVP in the management of mesothelioma with symptom control as a principal endpoint.
We all owe a debt of gratitude to these fine researchers. If you found any of these excerpts interesting, please read the studies in their entirety.
Haphazard Proliferation of Cytologically and Mesothelioma Tumors
By: Montwrobleski77
Colorectal Detox Acai Berry - Superb Quick Ideas to have Your Colorectal Detox Regular And Alternative Career In Health Services Easy Way To Yourself Educate Yourself On Speeches For The Best Man To Deliver A Truly Exceptional Speech Finding Proper Mesothelioma Information Accredited Stem Cell Banks Breast Care Some Hard Tips To Remember What Treatment Would I Have If I Had Your Cancer? Does Homeschooling Create Narrow & Bigoted Ideas To Their Children? Breast Cancer Symptom Cancer and the amazing healing powers of the Gerson therapy Finding Out If You Are Covered For Breast Reduction Surgery Dukes Colon Cancer Staging